<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Unknown</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/289F7529-FA9B-42C2-B4C7-4603DA25CC42"><gtr:id>289F7529-FA9B-42C2-B4C7-4603DA25CC42</gtr:id><gtr:name>Ludwig Institute for Cancer Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/65AF1713-F5D3-41D8-A71A-DA5E41A4F797"><gtr:id>65AF1713-F5D3-41D8-A71A-DA5E41A4F797</gtr:id><gtr:firstName>Vincenzo</gtr:firstName><gtr:surname>Cerundolo</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/84B59B79-B56D-45EA-9648-BCF8991B9A9B"><gtr:id>84B59B79-B56D-45EA-9648-BCF8991B9A9B</gtr:id><gtr:firstName>Suzanne</gtr:firstName><gtr:surname>Watt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0DD47AE4-BCAA-48E1-8B13-3F2428BDDA18"><gtr:id>0DD47AE4-BCAA-48E1-8B13-3F2428BDDA18</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>L.</gtr:otherNames><gtr:surname>Harris</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501975"><gtr:id>08C9860C-8C41-4DF9-963A-1625455BB051</gtr:id><gtr:title>A phase I trial in melanoma patients using dendritic cells pulsed with a novel synthetic iNKT cell agonist</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501975</gtr:grantReference><gtr:abstractText>Tumour immunology is now on a very solid and conceptual footing. The challenge remains to translate these results into the clinic. There is a great expectation that cancer vaccines will offer advantages over conventional cancer treatments . Vaccines are likely to produce fewer and milder side-effects than chemotherapy and radiotherapy as they specifically target cancer cells only. 

The ideal immune response to a cancer vaccine would be ?integrated , meaning that all components of the immune system, killer cells, helper cells and antibodies, are generated to target tumour cells, leading to the destruction of the cancer cells. Such integrated immune responses require that vaccination strategies facilitate an optimal cross-talk between different cells of the immune system. 

Current vaccination strategies, based on the use of recombinant attenuated viruses, are failing to trigger such an integrated response, since immune responses in patients vaccinated with current vaccination protocols are orders of magnitudes weaker than those immune responses observed during natural infections. Optimizing vaccination protocols requires a deeper understanding of the signals that the immune system coordinates to respond to pathogenic infection. Compounds that mimic these signals may therefore be exploited as adjuvants in current vaccination strategies. Advances in molecular technology have permitted the design of ?subunit? vaccines directed at protein targets, providing immunotherapy with a degree of specificity that was not possible using traditional vaccines based on live attenuated viruses.

Over the last few years we have characterised a series of synthetic compounds capable of activating a population of cells, called invariant NKT cells, which orchestrate the maturation of professional antigen presenting cells (dendritic cells) resulting in the activation of killer cells, helper cells and antibody producing cells. The results of these studies have been possible through a concerted effort between immunologists, structural biologists and organic chemists. 

We are now very keen to translate these results into the clinic to assess whether the results obtained in pre-clinical models can be applied to cancer patients and trigger an integrated cancer specific immune response.</gtr:abstractText><gtr:technicalSummary>Background: The overall aim of this research programme is to carry out a phase I clinical trial in melanoma patients to test a novel vaccination strategy bridging the adaptive and innate arms of the immune system. T cell responses to natural infection are orders of magnitude greater than those observed in patients vaccinated with current vaccination protocols. Optimizing vaccination protocols requires a deeper understanding of the signals that the immune system coordinates to respond to pathogenic infection. Compounds that mimic these signals may therefore be exploited as adjuvants in current vaccination strategies. Advances in molecular technology have permitted the design of ?subunit? vaccines directed at protein targets, providing immunotherapy with a degree of specificity that was not possible using traditional vaccines based on live attenuated viruses. 

Preclinical Results: We have described the property of invariant NKT (iNKT) cells to assist priming of antigen specific T lymphocytes. The results of these experiments were derived from a concerted effort between immunologists, structural biologists and organic chemists. 
Stimulation of iNKT cells in vivo significantly enhances immune responses to protein and peptide based vaccines, due to rapid iNKT dependent Dendritic Cell (DC) maturation. We have recently solved the crystal structure of CD1d molecules and measured the affinity of binding of soluble iNKT T cell receptor to CD1d molecules loaded with iNKT agonists. The results of these structural, kinetic and functional studies have led to the rational optimisation of a series of novel synthetic compounds capable of activating human and mouse iNKT cells, resulting in rapid DC maturation and T cell priming. Experiments carried out with human cells showed that the compound threitolceramide is capable of priming antigen specific T cells as efficiently as the iNKT cell agonist alpha-GalactosylCeramide. 

Research Plan: We are requesting funding to carry out a phase I clinical trial in melanoma patients to test the ability of threitolceramide to assist priming and expansion of melanoma specific T cell responses. Since it has recently been shown that alpha-GalactosylCeramide pulsed DC can expand iNKT cells in patients, we intend to pulse DC with threitolceramide and with melanoma peptide epitopes derived from the Melan-A and NY-ESO-1 proteins and inject them into high risk melanoma patients. The results of this trial will provide a platform for the design of effective T cell and antibody therapy against infectious diseases and cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-12-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>709991</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Institute for Cancer Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Ludwig Institute of Cancer Research</gtr:description><gtr:id>43480F35-3087-4D00-93CE-45D75530DCF2</gtr:id><gtr:impact>18550831 18453560</gtr:impact><gtr:outcomeId>537919F1A14-1</gtr:outcomeId><gtr:partnerContribution>Supply of reagents and clinical trial support and infrastructure</gtr:partnerContribution><gtr:piContribution>The Ludwig Institute for Cancer Research is providing funding and overall support for the formulation of GMP grade IMM47, which will be used for a Phase I clinical trial.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cancer Research UK</gtr:description><gtr:id>582DF8CC-DBEF-4FA9-BC5E-1C2BDB4A1FBA</gtr:id><gtr:impact>18550831 18453560</gtr:impact><gtr:outcomeId>5441ACB7D7B-1</gtr:outcomeId><gtr:partnerContribution>CRUK is the sponsor of the phase I clinical trial based on the injection of autologous DC pulsed with the iNKT cell agonist IMM47</gtr:partnerContribution><gtr:piContribution>We are currently testing several batches of liposomes formulated with the iNKT cell agonist IMM47 to identify the optical formulation and protocol to do toxicology tests.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School Work Experience</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>893625D3-AA6F-46A2-8C05-528C1F601AA1</gtr:id><gtr:impact>Where possible within the constraints of Health &amp;amp; Safety, the Unit welcomes sixth form students to carry out their work experience within the Unit - undertaking simple practical techniques and shadowing Unit members to get a better appreciation of a career in medical research. One student spent 1 week working in my Lab.

School asked for future opportunities</gtr:impact><gtr:outcomeId>GvNSLyxyXwc</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford Alumni</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A652B0FD-C482-4069-9B93-D03F1193EDA7</gtr:id><gtr:impact>Prof. Cerundolo gave a lecture on tumour immunology and cancer vaccines to a group of 130 Oxford Alumni (average age 60 years)

Talk was well received</gtr:impact><gtr:outcomeId>oAzHzYGfm4T</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ability of Invariant NKT cells to modulate the phenotype and function of Myeloid cells - Roche Glycart AG, Schleren, Zurich, Switzerland</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>86984338-1CF4-4F38-B281-125F8FDD4858</gtr:id><gtr:impact>Gave a talk to research Scientists at Roche to enhance their knowledge of new advance in the field of inflammation, and participated in discussions about translational research.

In discussions about potential collaboration/funding</gtr:impact><gtr:outcomeId>5450ba86043ec5.19231508</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>John Humphrey Lecture Series, Immunology Department, Imperial College London 'Novel insights into the Biology of Human Toll-like Receptor 7'</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7A48813C-F98D-460C-8774-7E62624A091F</gtr:id><gtr:impact>Students and Scientific Peers attended my talk, which was followed by meetings with members of the Faculty. This Improved the relations between our institutes.

Currently negotiating collaboration for a paper</gtr:impact><gtr:outcomeId>544f9d84118e07.22591224</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>https://www1.imperial.ac.uk/medicine/research/institutes/cipm/courses/jhss/</gtr:url><gtr:year>2011,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invariant NKT cells at the interface between adaptative and innate immune response - Edinburgh Immunology Group, University of Edinburgh</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E88A7C48-BE6E-4F4F-B3D3-9E6802B10E41</gtr:id><gtr:impact>Lecture given to The Edinburgh Immunology Group, University of Edinburgh, followed by informal discussions with the scientists

Currently setting up grant proposal for a new collaboration with Scientists from Edinburgh</gtr:impact><gtr:outcomeId>544faedc1ab165.76565962</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invariant NKT cells at the interface between adaptative and innate immune response - Peter Gorer Dept of Immunobiology, King's College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>2BCE50AE-A9D9-4350-BD27-2C3005089216</gtr:id><gtr:impact>80 Students attended the lecture and following Q&amp;amp;A session

Increase in requests about working/studying in my unit</gtr:impact><gtr:outcomeId>544faab78e4e29.10624263</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Centenary Celebrations</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7D79A024-5901-476D-A651-395E941732B7</gtr:id><gtr:impact>The event was attended by approx. 2500 members of the public.

The event was extremely well received and raised awareness into the activities carried out by the MRC Units in Oxford and beyond.</gtr:impact><gtr:outcomeId>eCxjr99qZDP</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oxford University Department for Continuing Education Human and Veterinary Vaccinology Course</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F1934848-E0F7-4A07-BD33-EDA802DF2537</gtr:id><gtr:impact>During the last 2 years, the Oxford University Department for Continuing Education http://www.conted.ox.ac.uk/courses/C900-1 
has launched a leading educational programme in Vaccinology, tailored to the needs of industry in the UK and beyond, by sharing the expertise of several investigators, both at the Institute for Animal Health and across the University of Oxford, complemented by the views and experience of distinguished outside speakers. The courses run in 2010 were fully subscribed and received very good feedback from the participants. The satisfaction scores were very high: 88% for the Human and Veterinary Vaccinology; 77% for the Clinical Vaccine Development course; and 81% for the Vaccine Biomanufacturing course.
In November 2011 Prof. Cerundolo gave a talk entitled 'An Introduction to Tumour Immunology'

Course was well attended</gtr:impact><gtr:outcomeId>AdujC2g5L82</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ability of Invariant NKT cells to modulate the phenotype and function of Myeloid cells - Institute for Immunity Transplantation and Infection, Stanford University, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4F8F4BF0-018D-4358-90A0-5693C1D61260</gtr:id><gtr:impact>150 Medical and research based Postgraduates and their lead Scientists attended the Seminar and following Q&amp;amp;A session

n/a</gtr:impact><gtr:outcomeId>5450bc818d98e4.53057235</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ability of Invariant NKT cells to modulate the phenotype and function of antigen presenting cells - Ludwig Maximilians University, Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AD7AAEDB-63C1-498C-A0E1-6FDA0E1B552D</gtr:id><gtr:impact>Inited to give a lecture in Germany

More students inquiring about coming here to work/study</gtr:impact><gtr:outcomeId>544fa617144668.73784470</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Harnessing invariant NKT cells to enhance antigen specific immune responses - Kennedy Seminar Series, University of Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7D41EC7E-2F83-4E90-8A54-14CA8F7481F2</gtr:id><gtr:impact>Students from the Kennedy Institute of Rheumatology attended the lecture, and the Q&amp;amp;A afterwards

Further requests for exchange of information between the units</gtr:impact><gtr:outcomeId>544fa90e481b71.80665283</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Magadalen College School</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DCD124BF-1FE9-4075-BA42-60CF7F273DE3</gtr:id><gtr:impact>Prof. Cerundolo gave a lecture at Magadalen College School, Oxford to 130 17-year olds on the career path of scientists in which he described training and job opportunities in biomedical research

School interested in future visits</gtr:impact><gtr:outcomeId>PN3dP8aVT7M</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>Pre-2006</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Annual Review 2008-09</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>59552A08-91D6-4757-ADE7-0A6E90A3FF1D</gtr:id><gtr:impact>General description of the my research programme to a general audience

general interests towards the research programmes that we are developing in my laboratory and within the MRC Human Immunology Unit.</gtr:impact><gtr:outcomeId>43B1EC5B80D</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A level student visits 2012</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>E1821BD5-606B-4B57-B001-3A61A9608B08</gtr:id><gtr:impact>2 students were hosted by members of my group for a &amp;quot;work experience week'

school would like to repeat the program in 2013</gtr:impact><gtr:outcomeId>KJWK3GV3oJx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>857627</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant (Novel invariant NKT cell agonists as adjuvants for antigen specific T and B cell responses)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>7E126CA8-31FE-4CA6-8F66-35786D222181</gtr:id><gtr:outcomeId>89BBC83A4200</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>G0501975</gtr:grantRef><gtr:id>1EB7AFD5-360C-406D-A0E1-FE4A2B00A23B</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fcafa84a53.65522203</gtr:outcomeId><gtr:patentId>CN101331146B</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF</gtr:description><gtr:grantRef>G0501975</gtr:grantRef><gtr:id>B6389DFD-BC86-46FD-AE04-B0B0E2C3762A</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>173338E92D0</gtr:outcomeId><gtr:patentId>CA2626997A</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>G0501975</gtr:grantRef><gtr:id>12B441D5-0EA8-43DC-8712-3A377D3D2EBF</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fcf769eaf6.50195815</gtr:outcomeId><gtr:patentId>6836514.7</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>G0501975</gtr:grantRef><gtr:id>3A29957D-BD6D-4A7B-9684-30C44F0560D3</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fd7967be69.02105845</gtr:outcomeId><gtr:patentId>13/231,403</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>G0501975</gtr:grantRef><gtr:id>EBAC9A5C-CE89-4A36-8E47-C8DAB13AE1FD</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fdcfd71198.98008727</gtr:outcomeId><gtr:patentId>13/464,299</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:description><gtr:grantRef>G0501975</gtr:grantRef><gtr:id>D3AB5F80-5744-46F6-ADDD-30389A6D92D6</gtr:id><gtr:impact>In this patent, which underpinned my subsequent application to the MRC for a phase I clinical trial, we described the use of and composition of matter of a novel family of iNKT cell agonists</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>58c7fd3d05a7e6.74534876</gtr:outcomeId><gtr:patentId>12/083,673</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Analogs of alpha ceramide (IMM47) and uses thereof</gtr:title><gtr:yearProtectionGranted>2007</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>3-HYDROXYANTHRANILIC ACID OR SALTS THEREOF1 FOR TREATING CANCER OR INFECTIONS</gtr:description><gtr:grantRef>G0501975</gtr:grantRef><gtr:id>DE662D6F-219E-41FE-806E-F6B143F51375</gtr:id><gtr:impact>Description of the use of iNKT cell agonists to abolish the suppressive activity of myeloid derived suppressor cells expanded during tumour growth and inflammatory processes</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>E2A1FBD4085</gtr:outcomeId><gtr:patentId>WO2009063241</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>New Cancer Treatment</gtr:title><gtr:yearProtectionGranted>2008</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>we are currently comparing different liposome formulation of the iNKT cell agonist IMM47</gtr:description><gtr:id>FC1724FD-DFB0-4A1E-9E25-B8E1C6E3C713</gtr:id><gtr:impact>Patent 18453560</gtr:impact><gtr:outcomeId>6065D951341</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>NKT cell agonists</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://europepmc.org/abstract/MED/18453562</gtr:url></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>457D7AC3-7FB4-445F-B7EC-2A6E72670162</gtr:id><gtr:title>[Glycosphingolipids Gb3 and iGb3. In vivo roles in hemolytic-uremic syndrome and iNKT cell function].</gtr:title><gtr:parentPublicationTitle>Der Pathologe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f71c646940318407a3861110bf2de944"><gtr:id>f71c646940318407a3861110bf2de944</gtr:id><gtr:otherNames>Porubsky S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0172-8113</gtr:issn><gtr:outcomeId>58aabcbebd0ae3.34665239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0CA7DC2A-7290-450A-B295-E5EEE0012522</gtr:id><gtr:title>Down-regulation of NKG2D and NKp80 ligands by Kaposi's sarcoma-associated herpesvirus K5 protects against NK cell cytotoxicity.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20d02bc2c32cfe6f4c97355b57afcfe4"><gtr:id>20d02bc2c32cfe6f4c97355b57afcfe4</gtr:id><gtr:otherNames>Thomas M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58aabcbf89f209.23388107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2AC2B30-EEE1-4EAF-9974-C7AB92776192</gtr:id><gtr:title>A single-chain H-2Db molecule presenting an influenza virus nucleoprotein epitope shows enhanced ability at stimulating CD8+ T cell responses in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2364e09ae5aa8bf7204f7ba871a2610a"><gtr:id>2364e09ae5aa8bf7204f7ba871a2610a</gtr:id><gtr:otherNames>Palmowski MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58aabcbe3c0555.20246531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DA7F2C5-1199-4723-82B3-BE2283A2936B</gtr:id><gtr:title>Rational development of high-affinity T-cell receptor-like antibodies.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3bd7185a0698864c4440b2dbd1fed93"><gtr:id>a3bd7185a0698864c4440b2dbd1fed93</gtr:id><gtr:otherNames>Stewart-Jones G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58aabcbe089025.54684937</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B042FF0-6C11-4DB5-861B-E4F217AA5956</gtr:id><gtr:title>Synthesis and biological activity of alpha-galactosyl ceramide KRN7000 and galactosyl (alpha1--&amp;gt;2) galactosyl ceramide.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b71cc096b28f5d38b81344d4bdd2b9bd"><gtr:id>b71cc096b28f5d38b81344d4bdd2b9bd</gtr:id><gtr:otherNames>Veerapen N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>pm_53cd4b5d4b56a15f9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6518AC51-BE91-41F9-AB70-8572BD960207</gtr:id><gtr:title>B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed032268c749fe13105b28653a67c1d5"><gtr:id>ed032268c749fe13105b28653a67c1d5</gtr:id><gtr:otherNames>Barral P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>58aabcbf0e2a59.57964934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9860E317-83C1-46A2-94AC-9AA30434A06A</gtr:id><gtr:title>Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb84b09f21c093abb7469985c504cd07"><gtr:id>cb84b09f21c093abb7469985c504cd07</gtr:id><gtr:otherNames>Speak AO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>B2DAFEE0E7E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10B0DFE8-A460-4F0C-9096-EBA9F99E7A99</gtr:id><gtr:title>Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a45bc2b3cb7e3f4064a9dce2caec9a"><gtr:id>49a45bc2b3cb7e3f4064a9dce2caec9a</gtr:id><gtr:otherNames>Silk JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58aabcbf34bf14.22982925</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B46490C-208D-4F42-9FFA-2FE59564D39D</gtr:id><gtr:title>Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fa373de3f0e9fb2a670e455fccae66e"><gtr:id>3fa373de3f0e9fb2a670e455fccae66e</gtr:id><gtr:otherNames>Barnes E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>58aabcbf5eed35.48478455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C7A7DE6-762F-403A-BB98-E36875356DAD</gtr:id><gtr:title>Phage display-derived recombinant antibodies with TCR-like specificity against alpha-galactosylceramide and its analogues in complex with human CD1d molecules.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/83d972dc5c6a23943bff292af7c649d9"><gtr:id>83d972dc5c6a23943bff292af7c649d9</gtr:id><gtr:otherNames>Denkberg G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>58aabcbfadfdf1.12900750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DBD35DB-88F5-4575-B466-5C291DAA79CD</gtr:id><gtr:title>Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/817d3278c27c6117071a3801798f218b"><gtr:id>817d3278c27c6117071a3801798f218b</gtr:id><gtr:otherNames>Matthews KE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>58aabcc02c6320.03781188</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FA2B299-304B-4E8A-A262-6C6296BF3214</gtr:id><gtr:title>Nonglycosidic agonists of invariant NKT cells for use as vaccine adjuvants.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/19ebdd07ae639843bb247d6c7c2982c4"><gtr:id>19ebdd07ae639843bb247d6c7c2982c4</gtr:id><gtr:otherNames>Reddy BG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>dtF3W3VWZyc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE0C660F-B387-4EE4-8368-26FDBF247B73</gtr:id><gtr:title>Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A.</gtr:title><gtr:parentPublicationTitle>Nature immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d09a00d7c724d63247a15b7e5419d9c5"><gtr:id>d09a00d7c724d63247a15b7e5419d9c5</gtr:id><gtr:otherNames>De Santo C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1529-2908</gtr:issn><gtr:outcomeId>M4N5ESMjzC5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>507FB709-F06B-4267-9789-93102B81984E</gtr:id><gtr:title>Structure and binding kinetics of three different human CD1d-alpha-galactosylceramide-specific T cell receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e0374cf703d528f0919afff7ec8853"><gtr:id>03e0374cf703d528f0919afff7ec8853</gtr:id><gtr:otherNames>Gadola SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>EAAB320B283</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>262FB4C2-5FC0-439B-9F33-0C2DF92D86F0</gtr:id><gtr:title>Analysis of frequency and phenotype of antigen-specific T cells.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac7e26fc7687dfd51f87121e4632ed91"><gtr:id>ac7e26fc7687dfd51f87121e4632ed91</gtr:id><gtr:otherNames>Stock A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>58aabcbe5fab98.30488815</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13B9C408-CD1C-4877-AC8D-E301B46A343A</gtr:id><gtr:title>Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/03e0374cf703d528f0919afff7ec8853"><gtr:id>03e0374cf703d528f0919afff7ec8853</gtr:id><gtr:otherNames>Gadola SD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>68215A79B3F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A4D783A-E2DF-4B58-9A63-B8C0453D9EA8</gtr:id><gtr:title>Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd7cfa24aca2bdff2a40d8bc27c2f1e"><gtr:id>cdd7cfa24aca2bdff2a40d8bc27c2f1e</gtr:id><gtr:otherNames>Salio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>FCACC4A7F04</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC951598-D8F9-4E0D-968D-31EAEEBCD530</gtr:id><gtr:title>Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7ce540024a50b8bd8ff7d2427850e4"><gtr:id>6d7ce540024a50b8bd8ff7d2427850e4</gtr:id><gtr:otherNames>Lopes L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>58aabcc0035da0.80278389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>315493CC-AF13-4EA8-B9C1-ED2E9C3085D4</gtr:id><gtr:title>Structures of an MHC class I molecule from B21 chickens illustrate promiscuous peptide binding.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68719213bb1c312f00046e91edb42c17"><gtr:id>68719213bb1c312f00046e91edb42c17</gtr:id><gtr:otherNames>Koch M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>58aabcc0566d31.67152643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8F57D52-5D3C-4658-AF06-BF7FD856E44D</gtr:id><gtr:title>The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a3d14f806abdcc1cebb3b589a32041b"><gtr:id>7a3d14f806abdcc1cebb3b589a32041b</gtr:id><gtr:otherNames>McCarthy C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>D4B327C00A5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9BD4348-87C6-44C4-BB84-7E825BAD0A2A</gtr:id><gtr:title>Structural and functional aspects of lipid binding by CD1 molecules.</gtr:title><gtr:parentPublicationTitle>Annual review of cell and developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/49a45bc2b3cb7e3f4064a9dce2caec9a"><gtr:id>49a45bc2b3cb7e3f4064a9dce2caec9a</gtr:id><gtr:otherNames>Silk JD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1081-0706</gtr:issn><gtr:outcomeId>58aabcbfd1ce89.40305020</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24107BFB-5B29-45EF-881C-2A2DE77C5DFF</gtr:id><gtr:title>Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6bb9933d7677bfa255cf9e7b6cc37e5b"><gtr:id>6bb9933d7677bfa255cf9e7b6cc37e5b</gtr:id><gtr:otherNames>Poulin LF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>MBXUbK8A2SH</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501975</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>